(Phase II/III study comparing Trabectedin (T) versus T plus tTF-NGR to entrap T inside the tumor in patients with metastatic and/or refractory soft tissue sarcoma (STS; 2nd line))

Beteiligte Wissenschaftler*innen:
Akad. Oberrat Dr. Dipl.-Stat. J. Gerß
Dr. rer. physiol. Veronika Weyer-Elberich

Studienleitung:
Univ.-Prof. Dr. med. C. Schliemann

The TRABTRAP study is a randomized, controlled trial, open-label, in patients with metastatic or refractory soft tissue sarcoma (STS). It evaluates the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy in patients with unresectable or metastatic disease after failure of, or contraindications to, anthracycline-based first-line therapy.
The primary objective is to determine whether the combination therapy prolongs progression-free survival compared with trabectedin alone.